On September 20-21, 2016 Allison Dudley, Executive Director and David Flynn, Counsel to the Board attended an inter-governmental working meeting at the Food and Drug Administration to discuss the oversight of drug compounding and the relationship between the activities of the FDA and the states. The meeting provided an opportunity to discuss each state’s regulatory framework, recent FDA guidance documents, changes to the FDA’s inspection procedures, and information sharing challenges and opportunities.
More Latest News
February 17, 2017
SB 0422 Relating to Health Insurance Coverage For Opioids Health Insurance Coverage For Opioids; Providing that a health insurance policy that covers abuse-deterrent opioid analgesic drug products may impose a prior authorization requirement for an abuse-deterrent opioid analgesic drug product … Continue reading
January 19, 2017
Please see updated information about the DEA’s suspension of McKesson Corporation and controlled substances Continue reading